Saxagliptin
- Generic Name
- Saxagliptin
- Brand Names
- Kombiglyze, Komboglyze, Onglyza, Qtern, Qternmet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25N3O2
- CAS Number
- 361442-04-8
- Unique Ingredient Identifier
- 8I7IO46IVQ
- Background
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
- Indication
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Lin Liao
- Target Recruit Count
- 300
- Registration Number
- NCT01703637
- Locations
- 🇨🇳
YuCheng people's hospital, Dezhou, Shandong, China
🇨🇳Hospital of SINOTRUK, Jinan, Shandong, China
🇨🇳Jinan central hospital, Jinan, Shandong, China
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT01662999
- Locations
- 🇺🇸
Icon Clinical Pharmacology, Omaha, Nebraska, United States
Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT01660386
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine, Shanghai, China
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 320
- Registration Number
- NCT01646320
- Locations
- 🇺🇸
Torrance Clinical Research Institute Inc., Lomita, California, United States
🇺🇸Diabetes Medical Center Of California, Northridge, California, United States
🇺🇸Cassidy Medical Group/Clinical Research Advantage, Vista, California, United States
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 315
- Registration Number
- NCT01619059
- Locations
- 🇺🇸
Beach Physicians Clinical Research Corp., Huntington Beach, California, United States
🇺🇸Torrance Clinical Research, Lomita, California, United States
🇺🇸Cassidy Medical Group/Clinical Research Advantage, Vista, California, United States
The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2165
- Registration Number
- NCT01608724
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1282
- Registration Number
- NCT01606007
- Locations
- 🇺🇸
Willamette Valley Clinical Studies, Eugene, Oregon, United States
🇺🇸Pmg Research Of Knoxville, Knoxville, Tennessee, United States
🇺🇸Excel Clinical Research, Llc, Houston, Texas, United States
Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT01552005
Saxagliptin and Atherosclerosis
- Conditions
- Interventions
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01552018
- Locations
- 🇳🇴
Center for Clinical Heart Research, Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway
Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 8
- Registration Number
- NCT01548651
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.